|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maomao C, He L, Dianqin S, Siyi H, Xinxin
Y, Fan Y, Shaoli Z, Changfa X, Lin L, Ji P and Wanqing C: Current
cancer burden in China: Epidemiology, etiology, and prevention.
Cancer Biol Med. 19:1121–1138. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Passaro A, Jänne PA, Mok T and Peters S:
Overcoming therapy resistance in EGFR-mutant lung cancer. Nat
Cancer. 2:377–391. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schimanski S, Wild PJ, Treeck O, Horn F,
Sigruener A, Rudolph C, Blaszyk H, Klinkhammer-Schalke M, Ortmann
O, Hartmann A and Schmitz G: Expression of the lipid transporters
ABCA3 and ABCA1 is diminished in human breast cancer tissue. Horm
Metab Res. 42:102–109. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Steinbach D, Gillet JP, Sauerbrey A, Gruhn
B, Dawczynski K, Bertholet V, de Longueville F, Zintl F, Remacle J
and Efferth T: ABCA3 as a possible cause of drug resistance in
childhood acute myeloid leukemia. Clin Cancer Res. 12:4357–4363.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matsumura Y, Sakai H, Sasaki M, Ban N and
Inagaki N: ABCA3-mediated choline-phospholipids uptake into
intracellular vesicles in A549 cells. FEBS Let. 581:3139–3144.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Overbeck TR, Arnemann J,
Waldmann-Beushausen R, Trümper L, Schöndube FA, Reuter-Jessen K and
Danner BC: ABCA3 phenotype in non-small cell lung cancer indicates
poor outcome. Oncology. 93:270–278. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goldman MJ, Craft B, Hastie M, Repečka K,
McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al:
Visualizing and interpreting cancer genomics data via the Xena
platform. Nat Biotechnol. 38:675–678. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bindea G, Mlecnik B, Hackl H, Charoentong
P, Tosolini M, Kirilovsky A, Fridman WH, Pagès F, Trajanoski Z and
Galon J: ClueGO: A Cytoscape plug-in to decipher functionally
grouped gene ontology and pathway annotation networks.
Bioinformatics. 25:1091–1093. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Szklarczyk D, Gable AL, Lyon D, Junge A,
Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork
P, et al: STRING v11: Protein-protein association networks with
increased coverage, supporting functional discovery in genome-wide
experimental datasets. Nucleic Acids Res. 47(D1): D607–D613. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hutchinson BD, Shroff GS, Truong MT and Ko
JP: Spectrum of lung adenocarcinoma. Semin Ultrasound CT MR.
40:255–264. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ruiz-Cordero R and Devine WP: Targeted
therapy and checkpoint immunotherapy in lung cancer. Surg Pathol
Clin. 13:17–33. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leonetti A, Sharma S, Minari R, Perego P,
Giovannetti E and Tiseo M: Resistance mechanisms to osimertinib in
EGFR-mutated non-small cell lung cancer. Br J Cancer. 121:725–737.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
de Lima LT, Bueno CT, Vivona D, Hirata RD,
Hirata MH, Hungria VT, Chiattone CS, Zanichelli MA, Chauffaille Mde
L and Guerra-Shinohara EM: Relationship between SLCO1B3 and ABCA3
polymorphisms and imatinib response in chronic myeloid leukemia
patients. Hematology. 20:137–142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu J, Ren L, Li S, Li W, Zheng X, Yang Y,
Fu W, Yi J, Wang J and Du G: The biology, function, and
applications of exosomes in cancer. Acta Pharm Sin B. 11:2783–2797.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Singh M, Yelle N, Venugopal C and Singh
SK: EMT: Mechanisms and therapeutic implications. Pharmacol Ther.
182:80–94. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Loh CY, Chai JY, Tang TF, Wong WF, Sethi
G, Shanmugam MK, Chong PP and Looi CY: The E-cadherin and
N-cadherin switch in epithelial-to-mesenchymal transition:
Signaling, therapeutic implications, and challenges. Cells.
8:11182019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kaminski WE, Piehler A and Wenzel JJ: ABC
A-subfamily transporters: Structure, function and disease. Biochim
Biophys Acta. 1762:510–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fish L, Navickas A, Culbertson B, Xu Y,
Nguyen HCB, Zhang S, Hochman M, Okimoto R, Dill BD, Molina H, et
al: Nuclear TARBP2 drives oncogenic dysregulation of RNA splicing
and decay. Mol Cell. 75:967–981.e9. 2019. View Article : Google Scholar : PubMed/NCBI
|
